Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells

International Journal of Urology

Volumn 19, Issue 6, 2012, Pages 565-574

  Tsapakidis, Konstantinos ^a   Vlachostergios, Panagiotis J ^a   Voutsadakis, Ioannis A ^c   Befani, Christina D ^b   Patrikidou, Anna ^d   Hatzidaki, Eleana ^a   Daliani, Danai D ^a   Moutzouris, George ^a   Liakos, Panagiotis ^b   Papandreou, Christos N ^a  

^a UNIVERSITY HOSPITAL OF LARISSA   (Greece)

^b UNIVERSITY OF THESSALY   (Greece)

^c LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Bombesin; Bortezomib; Endothelin 1; Prostate cancer; Proteasome

Indexed keywords

BOMBESIN; BORTEZOMIB; CASPASE 3; ENDOTHELIN 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; NEUROPEPTIDE; PROTEASOME; PROTEIN BAD; PROTEIN KINASE B; PROTEIN P21; PROTEIN P27; PROTEIN P44; PROTEIN P53; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; DOWN REGULATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; UPREGULATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-ASSOCIATED DEATH PROTEIN; BOMBESIN; BORONIC ACIDS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DOWN-REGULATION; ENDOTHELIN-1; HUMANS; INTERLEUKIN-8; MALE; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RNA, MESSENGER; SIGNAL TRANSDUCTION; TRANSLOCATION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84861483092     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2012.02967.x     Document Type: Article

References (52)

1. Mosca A, Berruti A, Russo L, Torta M, Dogliotti L. The neuroendocrine phenotype in prostate cancer: basic and clinical aspects. J. Endocrinol. Invest. 2005; 28: 141-5.
2. Reile H, Armatis PE, Schally AV. Characterization of high-affinity receptors for bombesin/gastrin releasing peptide on the human prostate cancer cell lines PC-3 and DU-145: internalization of receptor bound 125I-(Tyr4) bombesin by tumor cells. Prostate 1994; 25: 29-38.
3. Aprikian AG, Han K, Chevalier S, Bazinet M, Viallet J. Bombesin specifically induces intracellular calcium mobilization via gastrin-releasing peptide receptors in human prostate cancer cells. J. Mol. Endocrinol. 1996; 16: 297-306.
4. Logothetis C, Hoosein N. The inhibition of the paracrine progression of prostate cancer as an approach to early therapy of prostatic carcinoma. J. Cell. Biochem. 1992; 50 (Suppl 16H): 128-34.
5. Inoue A, Yanagisawa M, Kimura S etal. The human ET family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A. 1989; 86: 2863-7.
6. Rozengurt E. Signal transduction pathways in the mitogenic response to G protein coupled neuropeptide receptor agonists. J. Cell. Physiol. 1998; 177: 507-17.
7. Kroog GS, Jensen RT, Battey JF. Mammalian bombesin receptors. Med. Res. Rev. 1995; 12: 389-417.
8. Nelson JB, Hedican SP, George DJ etal. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat. Med. 1995; 1: 944-9.
9. Nelson JB, Chan-Tack K, Hedican SP etal. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996; 56: 663-8.
10. Li Q, Verma IM. NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2002; 2: 725-34.
11. Chen Z, Hagler J, Palombella VJ etal. Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin proteasome pathway. Genes Dev. 1995; 9: 1586-97.
12. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000; 408: 307-10.
13. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2002; 2: 594-604.
14. Reed JC. Mechanisms of apoptosis. Am. J. Pathol. 2000; 157: 1415-30.
15. Williams S, Pettaway C, Song R, Papandreou C, Logothetis C, McConkey DJ. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol. Cancer Ther. 2003; 2: 835-43.
16. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004; 5: 417-21.
17. Richardson PG, Barlogie B, Berenson J etal. A phase 2 study of bortezomib in relapsed, refractory myeloma. N. Engl. J. Med. 2003; 348: 2609-17.
18. Kane RC, Bross PF, Farrell AT, Pazdur R. Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy. Oncologist 2003; 8: 508-13.
19. Patrikidou A, Vlachostergios PJ, Voutsadakis IA etal. Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell Int. 2011; 11: 13-21.
20. Sumitomo M, Milowsky MI, Shen R etal. Neutral endopeptidase inhibits neuropeptide-mediated transactivation of the insulin-like growth factor receptor-Akt cell survival pathway. Cancer Res. 2001; 61: 3294-8.
21. Xiao D, Qu X, Weber HC. Activation of extracellular signal-regulated kinase mediates bombesin-induced mitogenic responses in prostate cancer cells. Cell. Signal. 2003; 15: 945-53.
22. Wu-Wong JR, Chiou WJ, Wang J. Extracellular signal-regulated kinases are involved in the antiapoptotic effect of endothelin-1. J. Pharmacol. Exp. Ther. 2000; 293: 514-21.
23. Papandreou CN, Logothetis CJ. Bortezomib as a potential treatment for prostate cancer. Cancer Res. 2004; 64: 5036-43.
24. Suh J, Payvandi F, Edelstein LC etal. Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate 2002; 52: 183-200.
25. Sweeney C, Li L, Shanmugam R etal. Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin. Cancer Res. 2004; 10: 5501-7.
26. Jin RJ, Lho Y, Connelly L etal. The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Res. 2008; 68: 6762-9.
27. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999; 59: 2615-22.
28. Adams J. Development of the proteasome inhibitor PS-341. Oncologist 2002; 7: 9-16.
29. Ikezoe T, Yang Y, Saito T, Koeffler HP, Taguchi H. Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci. 2004; 95: 271-5.
30. Sakai I, Miyake H, Terakawa T, Fujisawa M. Inhibition of tumor growth and sensitization to chemotherapy by RNA interference targeting interleukin-6 in the androgen-independent human prostate cancer PC3 model. Cancer Sci. 2011; 102: 769-75.
31. Papandreou CN, Daliani DD, Nix D etal. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol. 2004; 22: 2108-21.
32. An J, Sun YP, Adams J, Fisher M, Belldegrun A, Rettig MB. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin. Cancer Res. 2003; 9: 4537-45.
33. Thorpe JA, Christian PA, Schwarze SR. Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate 2008; 68: 200-9.
34. Christian PA, Thorpe JA, Schwarze SR. Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo. Cancer Biol. Ther. 2009; 8: 73-80.
35. Johnson TR, Stone K, Nikrad M etal. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003; 22: 4953-63.
36. Kandasamy K, Kraft AS. Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3′-untranslated region. Mol. Cancer Ther. 2008; 7: 1091-100.
37. Nikrad M, Johnson T, Puthalalath H, Coultas L, Adams J, Kraft AS. The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol. Cancer Ther. 2005; 4: 443-9.
38. Lashinger LM, Zhu K, Williams SA, Shrader M, Dinney CP, McConkey DJ. Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells. Cancer Res. 2005; 65: 4902-8.
39. Tu Z, Kelley VR, Collins T, Lee FS. I kappa B kinase is critical for TNF-alpha-induced VCAM1 gene expression in renal tubular epithelial cells. J. Immunol. 2001; 166: 6839-46.
40. Salido M, Gonzalez JL, Vilches J. Loss of mitochondrial membrane potential is inhibited by bombesin in etoposide-induced apoptosis in PC-3 prostate carcinoma cells. Mol. Cancer Ther. 2007; 6: 1292-9.
41. Nelson JB, Udan MS, Guruli G, Pflug BR. Endothelin-1 inhibits apoptosis in prostate cancer. Neoplasia. 2005; 7: 631-7.
42. Banerjee S, Hussain M, Wang Z etal. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 2007; 67: 3818-26.
43. Isaacs WB, Carter BS, Ewing CM. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res. 1991; 51: 4716-20.
44. Shi XB, Nesslinger NJ, Deitch AD, Gumerlock PH, deVere White RW. Complex functions of mutant p53 alleles from human prostate cancer. Prostate 2002; 51: 59-72.
45. He M, Rennie PS, Dragowska V, Nelson CC, Jia W. A mutant P53 can activate apoptosis through a mechanism distinct from those induced by wild type P53. FEBS Lett. 2002; 517: 151-4.
46. Levine L, Lucci JA III, Pazdrak B etal. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res. 2003; 63: 3495-502.
47. Osman I, Dai J, Mikhail M etal. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression. Cancer 2006; 107: 2628-36.
48. Kukreja P, Abdel-Mageed AB, Mondal D, Liu K, Agrawal KC. Up-regulation of CXCR4 expression in PC-3 cells by stromal-derived factor-1alpha (CXCL12) increases endothelial adhesion and transendothelial migration: role of MEK/ERK signaling pathway-dependent NF-kappaB activation. Cancer Res. 2005; 65: 9891-8.
49. Huang H, Cheville JC, Pan Y, Roche PC, Schmidt LJ, Tindall DJ. PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J. Biol. Chem. 2001; 276: 38830-6.
50. Dreicer R, Petrylak D, Agus D, Webb I, Roth B. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer. Clin. Cancer Res. 2007; 13: 1208-15.
51. Hainsworth JD, Meluch AA, Spigel DR etal. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial. Clin. Genitourin. Cancer 2007; 5: 278-83.
52. Morris MJ, Kelly WK, Slovin S etal. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer. J. Urol. 2007; 178: 2378-83.